Top Markets
Coin of the day
Perseus Proteomics Inc. Perseus Proteomics Inc.

Perseus Proteomics Inc.

4882
Rangering i aksjer #30415
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology... Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Aksjekurs
$0.91993619
Markedsverdi
$16.95M
Endring (1 dag)
-2.76%
Endring (1 år)
-63.00%
Land
JP
Handel Perseus Proteomics Inc. (4882)

Kategori

Inntekter for Perseus Proteomics Inc. (4882)
Inntekter i 2026 TTM: 0
Ifølge Perseus Proteomics Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Perseus Proteomics Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$33.59B -
US
$25.20B -
US
$8.70B -
US
$21.39B -
CH
$5.95B -
US